ClearBridge Investments
ALNY icon

ClearBridge Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

ClearBridge Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379M Sell
1,259,483
-96,553
-7% -$29.1M 0.31% 74
2026
Q1 		$449M Buy
1,356,036
+759,023
+127% +$258M 0.39% 65
2025
Q4 		$237M Sell
597,013
-25,422
-4% -$11.3M 0.19% 116
2025
Q3 		$284M Buy
622,435
+65,336
+12% +$26.6M 0.21% 109
2025
Q2 		$182M Buy
557,099
+549,322
+7,063% +$152M 0.15% 142
2025
Q1 		$2.1M Buy
+7,777
New +$2M ﹤0.01% 604
2023
Q3 		– Sell
-83,185
Closed -$15.8M – 689
2023
Q2 		$15.8M Buy
83,185
+6,911
+9% +$1.37M 0.01% 468
2023
Q1 		$15.3M Buy
76,274
+19,614
+35% +$4.12M 0.01% 469
2022
Q4 		$13.5M Buy
+56,660
New +$12.1M 0.01% 484
2020
Q3 		– Sell
-365
Closed -$54K – 788
2020
Q2 		$54K Hold
365
– – ﹤0.01% 784
2020
Q1 		$40K Sell
365
-12
-3% -$1.39K ﹤0.01% 791
2019
Q4 		$44K Hold
377
– – ﹤0.01% 841
2019
Q3 		$30K Hold
377
– – ﹤0.01% 888
2019
Q2 		$27K Hold
377
– – ﹤0.01% 911
2019
Q1 		$35K Hold
377
– – ﹤0.01% 875
2018
Q4 		$27K Hold
377
– – ﹤0.01% 933
2018
Q3 		$33K Hold
377
– – ﹤0.01% 953
2018
Q2 		$37K Sell
377
-1,745
-82% -$173K ﹤0.01% 895
2018
Q1 		$253K Sell
2,122
-394
-16% -$50.8K ﹤0.01% 731
2017
Q4 		$320K Sell
2,516
-1,502
-37% -$189K ﹤0.01% 719
2017
Q3 		$472K Sell
4,018
-219
-5% -$18.7K ﹤0.01% 689
2017
Q2 		$338K Buy
4,237
+3,134
+284% +$200K ﹤0.01% 712
2017
Q1 		$57K Hold
1,103
– – ﹤0.01% 862
2016
Q4 		$41K Buy
1,103
+18
+2% +$754 ﹤0.01% 895
2016
Q3 		$74K Buy
1,085
+491
+83% +$34.6K ﹤0.01% 834
2016
Q2 		$33K Buy
+594
New +$37.4K ﹤0.01% 893

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments's ALNY Position: Q2 2026 in Review

ClearBridge Investments reduced its Alnylam Pharmaceuticals (ALNY) stake by 7.1% in Q2 2026, selling an estimated $29.1M and leaving 1,259,483 shares worth $379M. The position accounts for 0.31% of the portfolio, ranked #74.

ClearBridge Investments first reported a position in ALNY in Q2 2016 and has held it in 26 quarters since. The position peaked at $449M in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • ClearBridge Investments held 1,259,483 shares of Alnylam Pharmaceuticals worth $379M as of Q2 2026.
  • ClearBridge Investments sold 96,553 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $29.1M.
  • Alnylam Pharmaceuticals made up 0.31% of ClearBridge Investments's portfolio in Q2 2026, its #74 holding.
  • ClearBridge Investments first reported a position in Alnylam Pharmaceuticals in Q2 2016 and has held it in 26 quarters since.
  • ClearBridge Investments's Alnylam Pharmaceuticals position peaked at $449M in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on ClearBridge Investments's 13F filing for Q2 2026, filed 13 Aug 2026.